Accepted for Publication: October 22, 2021.
Published Online: January 31, 2022. doi:10.1001/jamaneurol.2021.5205
Corresponding Author: Massimo Filippi, MD, Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132 Milan, Italy (filippi.massimo@hsr.it).
Author Contributions: Drs Cecchetti and Spinelli had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Filippi, Cecchetti, Vezzulli, Falini, Agosta.
Acquisition, analysis, or interpretation of data: Cecchetti, Spinelli, Agosta.
Drafting of the manuscript: Filippi, Cecchetti, Spinelli, Vezzulli.
Critical revision of the manuscript for important intellectual content: Filippi, Cecchetti, Spinelli, Falini, Agosta.
Statistical analysis: Spinelli.
Administrative, technical, or material support: Spinelli.
Supervision: Filippi, Spinelli, Falini.
Other: Vezzulli.
Other (literature review, figure creation): Cecchetti.
Conflict of Interest Disclosures: Dr Filippi reported receiving personal fees from Alexion Pharmaceuticals, Almirall SA, Bayer AG, Biogen Inc, Celgene Corporation, Eli Lilly & Company, Genzyme, Merck Serono, Novartis International AG, La Roche AG, Sanofi SA, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd; receiving institutional grants from Biogen Idec, Merck Serono, Novartis International AG, La Roche AG, and Teva Pharmaceutical Industries Ltd outside the submitted work; and serving as editor-in-chief of the Journal of Neurology, associate editor of Human Brain Mapping, associate editor of Radiology, and associate editor of Neurological Sciences. Dr Agosta reported receiving personal fees for consulting services and/or speaking activities from F. Hoffmann-La Roche AG, Biogen Inc, and Philips outside the submitted work; serving as the associate editor of NeuroImage: Clinical; and receiving research support from Italian Ministry of Health, AriSLA (Fondazione Italiana di Ricerca per la SLA), and the European Research Council. No other disclosures were reported.
6.Sperling
RA , Jack
CR
Jr , Black
SE ,
et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup.
Alzheimers Dement. 2011;7(4):367-385. doi:
10.1016/j.jalz.2011.05.2351
PubMedGoogle ScholarCrossref 9.Klein
G , Bracoud
L , Purcell
DD ,
et al. Calibration of a simplified ARIA-E MRI severity scale suitable for clinical practice.
Alzheimers Dement. 2020;16(S2):e041110. doi:
10.1002/alz.041110Google Scholar 14.Page
MJ , Moher
D , Bossuyt
PM ,
et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.
BMJ. 2021;372:n160. doi:
10.1136/bmj.n160
PubMedGoogle Scholar 17.Doody
RS , Thomas
RG , Farlow
M ,
et al; Alzheimer’s Disease Cooperative Study Steering Committee; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease.
N Engl J Med. 2014;370(4):311-321. doi:
10.1056/NEJMoa1312889
PubMedGoogle ScholarCrossref 19.Brody
M , Liu
E , Di
J ,
et al. A phase II, randomized, double-blind, placebo-controlled study of safety, pharmacokinetics, and biomarker results of subcutaneous bapineuzumab in patients with mild to moderate Alzheimer’s disease.
J Alzheimers Dis. 2016;54(4):1509-1519. doi:
10.3233/JAD-160369
PubMedGoogle ScholarCrossref 20.Delnomdedieu
M , Duvvuri
S , Li
DJ ,
et al. First-in-human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease.
Alzheimers Res Ther. 2016;8(1):12. doi:
10.1186/s13195-016-0177-y
PubMedGoogle ScholarCrossref 21.Salloway
S , Sperling
R , Fox
NC ,
et al; Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease.
N Engl J Med. 2014;370(4):322-333. doi:
10.1056/NEJMoa1304839
PubMedGoogle ScholarCrossref 22.Vandenberghe
R , Rinne
JO , Boada
M ,
et al; Bapineuzumab 3000 and 3001 Clinical Study Investigators. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials.
Alzheimers Res Ther. 2016;8(1):18. doi:
10.1186/s13195-016-0189-7
PubMedGoogle ScholarCrossref 23.Salloway
SP , Sperling
R , Fox
NC ,
et al. Long-term follow up of patients with mild-to-moderate Alzheimer’s disease treated with bapineuzumab in a phase III, open-label, extension study.
J Alzheimers Dis. 2018;64(3):689-707. doi:
10.3233/JAD-171157
PubMedGoogle ScholarCrossref 26.Guthrie
H , Honig
LS , Lin
H ,
et al. Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer’s disease treated with escalating doses for up to 133 weeks.
J Alzheimers Dis. 2020;76(3):967-979. doi:
10.3233/JAD-200134
PubMedGoogle ScholarCrossref 27.Ostrowitzki
S , Lasser
RA , Dorflinger
E ,
et al; Scarlet Road Investigators. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease.
Alzheimers Res Ther. 2017;9(1):95. Published correction appears in
Alzheimers Res Ther. 2018;10(1):99. doi:
10.1186/s13195-017-0318-y
PubMedGoogle ScholarCrossref 28.Abi-Saab
D , Andjelkovic
M , Pross
N ,
et al. Update on the safety and tolerability of gantenerumab in the ongoing open-label extension (OLE) of the Marguerite Road study in patients with mild Alzheimer's disease (AD) after approximately two years of study duration.
Alzheimers Dement. 2018;14(suppl 7):P241. doi:
10.1016/j.jalz.2018.06.2381Google Scholar 29.Andjelkovic
M , Abi-Saab
D , Delmar
P ,
et al. Update on the safety and tolerability of gantenerumab in the ongoing open-label extension of the Scarlet Road study in patients with prodromal Alzheimer's disease after approximately 2 years of study duration.
Alzheimers Dement. 2018;14(suppl 7):P241-P242. doi:
10.1016/j.jalz.2018.06.2382Google Scholar 33.Swanson
CJ , Zhang
Y , Dhadda
S ,
et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody.
Alzheimers Res Ther. 2021;13(1):80. doi:
10.1186/s13195-021-00813-8
PubMedGoogle ScholarCrossref 38.Arrighi
HM , Barakos
J , Barkhof
F ,
et al. Amyloid-related imaging abnormalities–haemosiderin (ARIA-H) in patients with Alzheimer’s disease treated with bapineuzumab: a historical, prospective secondary analysis.
J Neurol Neurosurg Psychiatry. 2016;87(1):106-112.
PubMedGoogle Scholar 39.Ketter
N , Brashear
HR , Bogert
J ,
et al. Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer’s disease patients.
J Alzheimers Dis. 2017;57(2):557-573. doi:
10.3233/JAD-160216
PubMedGoogle ScholarCrossref 40.Brashear
HR , Ketter
N , Bogert
J , Di
J , Salloway
SP , Sperling
R . Clinical evaluation of amyloid-related imaging abnormalities in bapineuzumab phase III studies.
J Alzheimers Dis. 2018;66(4):1409-1424. doi:
10.3233/JAD-180675
PubMedGoogle ScholarCrossref 42.Martens
RM , Bechten
A , Ingala
S ,
et al. The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer’s patients: an interobserver study.
Eur Radiol. 2018;28(3):1215-1226. doi:
10.1007/s00330-017-5022-6
PubMedGoogle ScholarCrossref 43.Carlson
C , Estergard
W , Oh
J ,
et al. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer’s disease study cohorts from phase 3 trials of semagacestat and solanezumab.
Alzheimers Dement. 2011;7(4):396-401. doi:
10.1016/j.jalz.2011.05.2353PubMedGoogle ScholarCrossref 45.VandeVrede
L , Gibbs
DM , Koestler
M ,
et al. Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab.
Alzheimers Dement (Amst). 2020;12(1):e12101. doi:
10.1002/dad2.12101
PubMedGoogle Scholar 48.Tolar
M , Abushakra
S , Hey
JA , Porsteinsson
A , Sabbagh
M . Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval.
Alzheimers Res Ther. 2020;12(1):95. doi:
10.1186/s13195-020-00663-w
PubMedGoogle ScholarCrossref